Skip to main content

Table 6 Differences in laboratory tests, inflammation-based prognostic scores, and nutrition index according to Clavien-Dindo gradesa

From: Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy

 

CD0 group (n = 61)

CD1/2 group (n = 44)

CD3/4 group (n = 10)

P Value

Baseline

     HB (g/L)

129 (66–155)

121 (64–170)

112 (72–159)

0.284

     WBC (×109/L)

5.9 (3.6–13.9)

6.4 (3.6–14.2)

8.1 (3.9–10.2)

0.109

     NEU (×109/L)

3.6 (2.2–10.9)

3.9 (2.0–11.7)

4.8 (1.4–7.7)

0.136

     LYM (×109/L)

1.7 (0.7–3.1)

1.8 (0.6–3.0)

2.0 (1.4–2.4)

0.238

     PLT (×109/L)

298.0 (96.0–639.0)

295.0 (141.0–599.0)

301.5 (166.0–438.0)

0.784

     ALB (g/L)

42.0 (35.0–49.0)

41.0 (28.0–47.0)

39.0 (25.0–48.0)

0.631

     ALT (U/L)

14.0 (5.0–75.0)

14.5 (5.0–58.0)

13.0 (7.0–59.0)

0.888

     AST (U/L)

17.0 (10.0–56.0)

15.0 (8.0–73.0)

19.5 (10.0–37.0)

0.473

     ALP (U/L)

56.0 (24.0–109.0)

59.5 (25.0–123.0)

71.5 (31.0–99.0)

0.137

     Scr (mg/dL)

0.82 (0.48–1.20)

0.86 (0.53–1.28)

0.81 (0.68–1.59)

0.593

     aPTT (second)

29.8 (23.0–37.2)

29.6 (24.9–38.6)

28.6 (24.9–33.1)

0.315

     PT (second)

10.9 (9.3–12.8)

11.0 (9.0–13.1)

11.1 (9.5–12.7)

0.765

     INR

0.96 (0.82–1.12)

0.97 (0.79–1.16)

0.98 (0.84–1.11)

0.883

     PNI

50.2 (40.4–61.8)

50.6 (34.2–60.0)

49.7 (33.0–60.2)

0.954

     NLR

2.5 (0.7–6.6)

2.2 (1.0–9.5)

2.4 (0.7–7.8)

0.805

     PLR

181.9 (67.6–557.7)

179.1 (73.8–487.0)

171.1 (78.3–256.9)

0.683

Preoperative

     HB (g/L)

116 (86–152)

115 (76–160)

117 (91–125)

0.810

     WBC (×109/L)

4.7 (2.3–11.7)

4.7 (2.7–11.9)

5.8 (3.0–9.7)

0.598

     NEU (×109/L)

2.7 (0.7–8.8)

2.6 (1.2–9.1)

3.0 (1.5–7.8)

0.755

     LYM (×109/L)

1.5 (0.5–3.4)

1.6 (0.4–2.7)

1.3 (0.6–2.9)

0.835

     PLT (×109/L)

218.0 (73.0–398.0)

202.0 (91.0–583.0)

216.5 (167.0–276.0)

0.861

     ALB (g/L)

40.0 (27.0–48.0)

39.5 (26.0–52.0)

39.0 (32.0–41.0)

0.541

     ALT (U/L)

17.0 (6.0–72.0)

14.0 (6.0–52.0)

15.5 (11.0–43.0)

0.431

     AST (U/L)

20.0 (12.0–75.0)

19.0 (11.0–42.0)

19.0 (12.0–42.0)

0.671

     ALP (U/L)

61.5 (21.0–142.0)

59.5 (25.0–106.0)

63.5 (35.0–163.0)

0.887

     Scr (mg/dL)

0.78 (0.43–1.39)

0.78 (0.38–1.55)

0.75 (0.63–1.34)

0.874

     aPTT (second)

29.9 (24.2–41.5)

29.7 (20.7–37.5)

31.0 (26.1–34.6)

0.979

     PT (second)

10.5 (9.4–13.1)

10.9 (9.4–13.4)

10.5 (9.6–11.7)

0.196

     INR

0.93 (0.83–1.15)

0.97 (0.83–1.18)

0.94 (0.85–1.01)

0.147

     CRPb (mg/L)

1.1 (0.3–51.1)

1.3 (0.4–68.6)

1.8 (0.5–13.9)

0.502

     PNI

46.8 (30.5–59.9)

46.0 (33.2–62.1)

45.4 (37.2–54.3)

0.801

     NLR

1.7 (0.6–9.6)

1.9 (0.6–9.7)

2.0 (0.8–10.1)

0.811

     PLR

134.6 (38.2–574.1)

123.4 (44.7–640.7)

148.3 (66.1–392.1)

0.714

     GPSb,c

   

0.804

          Score 0

43 (81.1)

30 (76.9)

7 (87.5)

 

          Score 1

8 (15.1)

6 (15.4)

0 (0.0)

 

          Score 2

2 (3.8)

3 (7.7)

1 (12.5)

 

     PIb,c

   

0.572

          Score 0

49 (92.5)

35 (89.7)

7 (87.5)

 

          Score 1

4 (7.5)

4 (10.3)

1 (12.5)

 
  1. ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; HB, hemoglobin; INR, international normalized ratio; LYM, lymphocyte count; NEU, neutrophil count; NLR, neutrophil–lymphocyte ratio; PI, Prognostic Index; PLR, platelet–lymphocyte ratio; PLT, platelet count; PNI, prognostic nutritional index; PT, prothrombin; Scr, serum creatinine; WBC, white blood cell count
  2. aData are presented as median (range) unless indicated otherwise
  3. bData retrieved from 100 patients, including 53 patients in CD0 group, 39 patients in CD1/2 group, and 8 patients in CD3/4 group
  4. cData are presented as number (percentage)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us